These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18442323)

  • 1. A highly sensitive diagnostic assay for aggregate-related diseases, including prion diseases and Alzheimer's disease.
    Birkmann E; Henke F; Funke SA; Bannach O; Riesner D; Willbold D
    Rejuvenation Res; 2008 Apr; 11(2):359-63. PubMed ID: 18442323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An ultrasensitive assay for diagnosis of Alzheimer's disease.
    Funke SA; Birkmann E; Henke F; Görtz P; Lange-Asschenfeldt C; Riesner D; Willbold D
    Rejuvenation Res; 2008 Apr; 11(2):315-8. PubMed ID: 18328004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interesting not only as differential Alzheimer dementia diagnosis. Bovine spongiform encephalopathy and other prion diseases].
    Kretzschmar H
    MMW Fortschr Med; 2000 Sep; 142(39):34-8. PubMed ID: 11072695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Counting of single prion particles bound to a capture-antibody surface (surface-FIDA).
    Birkmann E; Henke F; Weinmann N; Dumpitak C; Groschup M; Funke A; Willbold D; Riesner D
    Vet Microbiol; 2007 Aug; 123(4):294-304. PubMed ID: 17499942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review: membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease.
    Jeffrey M
    Neuropathol Appl Neurobiol; 2013 Apr; 39(3):196-216. PubMed ID: 23171056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration.
    Costanzo M; Zurzolo C
    Biochem J; 2013 May; 452(1):1-17. PubMed ID: 23614720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filtration of protein aggregates increases the accuracy for diagnosing prion diseases in brain biopsies.
    Wemheuer WM; Wrede A; Gawinecka J; Zerr I; Schulz-Schaeffer WJ
    J Neuropathol Exp Neurol; 2013 Aug; 72(8):758-67. PubMed ID: 23860029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comments on present-day spread and epidemiology of BSE and prion diseases].
    Bodemer W; Kaup FJ
    Gesundheitswesen; 2004 Feb; 66 Suppl 1():S21-5. PubMed ID: 14770333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein aggregation and prionopathies.
    Renner M; Melki R
    Pathol Biol (Paris); 2014 Jun; 62(3):162-8. PubMed ID: 24698014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capillary electromigration based techniques in diagnostics of prion protein caused diseases.
    Sobrova P; Ryvolova M; Adam V; Kizek R
    Electrophoresis; 2012 Dec; 33(24):3644-52. PubMed ID: 23161211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational detection of prion protein with biarsenical labeling and FlAsH fluorescence.
    Coleman BM; Nisbet RM; Han S; Cappai R; Hatters DM; Hill AF
    Biochem Biophys Res Commun; 2009 Mar; 380(3):564-8. PubMed ID: 19285001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic research on BSE transmission to people].
    Bodemer W; Kaup FJ
    Dtsch Tierarztl Wochenschr; 2002 Aug; 109(8):338-41. PubMed ID: 12224460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM; van Dam AM; Drukarch B
    Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics applications in prion biology and structure.
    Moore RA; Faris R; Priola SA
    Expert Rev Proteomics; 2015 Apr; 12(2):171-84. PubMed ID: 25795148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases.
    Klajnert B; Cortijo-Arellano M; Bryszewska M; Cladera J
    Biochem Biophys Res Commun; 2006 Jan; 339(2):577-82. PubMed ID: 16310169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanical stress and formation of protein aggregates in neurodegenerative disorders.
    Hachiya NS; Kozuka Y; Kaneko K
    Med Hypotheses; 2008; 70(5):1034-7. PubMed ID: 17910993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
    Gadad BS; Britton GB; Rao KS
    J Alzheimers Dis; 2011; 24 Suppl 2():223-32. PubMed ID: 21460436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the mechanisms of protein misfolding and aggregation in amyloidogenic diseases derived from pressure studies.
    Foguel D; Silva JL
    Biochemistry; 2004 Sep; 43(36):11361-70. PubMed ID: 15350123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
    Ferreira ST; Vieira MN; De Felice FG
    IUBMB Life; 2007; 59(4-5):332-45. PubMed ID: 17505973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
    Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
    ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.